Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …

Highlights•46 participants from 15 countries across Europe, Asia and the USA contributed to
the ESGO–ESMO–ESP consensus conference.•Recommendations cover diagnosis and …

Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

PURPOSE ATHENA (ClinicalTrials. gov identifier: NCT03522246) was designed to evaluate
rucaparib first-line maintenance treatment in a broad patient population, including those …

Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

Clinical workflows in oncology rely on predictive and prognostic molecular biomarkers.
However, the growing number of these complex biomarkers tends to increase the cost and …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …